CARLSBAD, Calif. – November 19, 2012 - GreenMoun

CARLSBAD, Calif. – November 19, 2012 - GreenMountain Development Corp (Pinksheet: GMND), announced today that GMND director and C. Trade CEO,Nick Kontonicolas, is negotiating domestic and international licensing rightsfor the GMND Bi-Agra™ agricultural products with a major biotech firm which hasthe technological expertise to manufacture and produce microbial products undercontrolled conditions.  The company hopesto conclude the negotiations this month and expand production of Bi-Agra™ intointernational markets in 2013.  TheBi-Agra™ products have demonstrated increased yields for many food and fuelcrops.GreenMountain and strategic partner C. Trade want to expand Bi-Agra™ manufacturingcapacity by licensing the technology to a major biotech firm capable of directproduction and distribution rather than using contract manufacturing and selfdistribution. The company has received numerous international inquiries to useand distribute the Bi-Agra™ agricultural products that increase plant healthand product yields. C. Trade is reviewing different business structures in itsquest to integrate into the biotech arena.About Green Mountain Development CorpGreen MountainDevelopment Corp provides project development services for capital providersand technology operators and distributes licensed products related to theenergy, agricultural and environmental sectors.  About C.Trade GroupC. Trade Group, Nick Kontonicolas, Presidentand Affiliates have interests in energy exploration and logistics, real estate,transportation and technology with affiliated offices in New York, Shanghai,California, Calgary, Athens, Jinzhou, China and Abu Dhabi.  Mr. Kontonicolas can be contacted at +1 917297-5571 or at ctradeusa@juno.com   Investors andmedia contact Robert Brehm at 619/488-3744 (bob@greenbizness.com) or visit thecorporate website www.GreenBizness.comfor news and updates.  The information contained in this press releaseincludes forward-looking statements. Forward-looking statements usually containthe words "estimate," "anticipate," "believe,""expect" or similar expressions that involve risks and uncertainties.These risks and uncertainties include the company'sstatus as a development stage company with uncertain profitability, need forsignificant capital, uncertainty concerning market acceptance of its products,competition, limited service and manufacturing facilities, dependence ontechnological developments and protection of its intellectual property. Thecompany's actual results coulddiffer materially from those discussed herein.

test